MA32781B1 - Arycyclohexylethers de dihydrotetrazabenzoazulenes pour emploi en tant qu'antagonistes du recepteur v1a de la vasopressine - Google Patents

Arycyclohexylethers de dihydrotetrazabenzoazulenes pour emploi en tant qu'antagonistes du recepteur v1a de la vasopressine

Info

Publication number
MA32781B1
MA32781B1 MA33827A MA33827A MA32781B1 MA 32781 B1 MA32781 B1 MA 32781B1 MA 33827 A MA33827 A MA 33827A MA 33827 A MA33827 A MA 33827A MA 32781 B1 MA32781 B1 MA 32781B1
Authority
MA
Morocco
Prior art keywords
disorders
arylcyclohexyl
concerns
ether derivatives
dihydrotetrazapenzoazole
Prior art date
Application number
MA33827A
Other languages
Arabic (ar)
English (en)
Inventor
Patrick Schnider
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA32781B1 publication Critical patent/MA32781B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES DÉRIVÉS DE TYPE ARYLCYCLOHEXYLÉTHER DE DIHYDROTÉTRAZABENZOAZULÈNE, PLUS PRÉCISÉMENT DES DÉRIVÉS DE TYPE ARYLCYCLOHEXYLÉTHERS DE 5,6-DIHYDRO-4H-2,3,5,10B-TÉTRAZA-BENZO[E]AZULÈNE DE FORMULE (I) OÙ R1, R2 ET R3 SONT TELS QUE DÉCRITS DANS LA PRÉSENTE INVENTION. LES COMPOSÉS SELON L'INVENTION AGISSENT EN TANT QUE MODULATEURS DES RÉCEPTEURS V1A, ET EN PARTICULIER EN TANT QU'ANTAGONISTES DES RÉCEPTEURS V1A. LA PRÉSENTE INVENTION CONCERNE ÉGALEMENT LEUR FABRICATION, LES COMPOSITIONS PHARMACEUTIQUES LES INCLUANT ET LEUR EMPLOI EN TANT QUE MÉDICAMENT. LES PRINCIPES ACTIFS SELON L'INVENTION PEUVENT ÊTRE EMPLOYÉS EN TANT QUE PRODUITS THÉRAPEUTIQUES À ACTION PÉRIPHÉRIQUE OU CENTRALE DANS LES ÉTATS DE DYSMÉNORRHÉE, DE DYSFONCTIONNEMENT SEXUEL CHEZ L'HOMME OU LA FEMME, D'HYPERTENSION, D'INSUFFISANCE CARDIAQUE CHRONIQUE, DE SÉCRÉTION INADAPTÉE DE VASOPRESSINE, DE CIRRHOSE DU FOIE, DE SYNDROME NÉPHROTIQUE, D'ANXIÉTÉ, DE TROUBLES DÉPRESSIFS, DE TROUBLES OBSESSIONNELS COMPULSIFS, DE TROUBLES DU SPECTRE AUTISTIQUE, DE SCHIZOPHRÉNIE ET DE COMPORTEMENT AGRESSIF.
MA33827A 2008-11-28 2011-05-10 Arycyclohexylethers de dihydrotetrazabenzoazulenes pour emploi en tant qu'antagonistes du recepteur v1a de la vasopressine MA32781B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08170188 2008-11-28
PCT/EP2009/065354 WO2010060836A1 (fr) 2008-11-28 2009-11-18 Arylcyclohexyléthers de dihydrotétrazabenzoazulènes pour emploi en tant qu'antagonistes du récepteur v1a de la vasopressine

Publications (1)

Publication Number Publication Date
MA32781B1 true MA32781B1 (fr) 2011-11-01

Family

ID=41382009

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33827A MA32781B1 (fr) 2008-11-28 2011-05-10 Arycyclohexylethers de dihydrotetrazabenzoazulenes pour emploi en tant qu'antagonistes du recepteur v1a de la vasopressine

Country Status (32)

Country Link
US (2) US8227458B2 (fr)
EP (1) EP2370441B1 (fr)
JP (1) JP5452608B2 (fr)
KR (1) KR101359742B1 (fr)
CN (1) CN102227428B (fr)
AR (2) AR074409A1 (fr)
AU (1) AU2009319123B2 (fr)
BR (1) BRPI0922303B1 (fr)
CA (1) CA2743976C (fr)
CO (1) CO6341478A2 (fr)
CR (1) CR20110220A (fr)
CY (1) CY1115435T1 (fr)
DK (1) DK2370441T3 (fr)
EC (1) ECSP11011089A (fr)
ES (1) ES2431279T3 (fr)
HK (1) HK1160642A1 (fr)
HR (1) HRP20131067T1 (fr)
IL (1) IL212122A (fr)
MA (1) MA32781B1 (fr)
MX (1) MX2011005596A (fr)
MY (1) MY150837A (fr)
NZ (1) NZ592076A (fr)
PE (1) PE20110582A1 (fr)
PL (1) PL2370441T3 (fr)
PT (1) PT2370441E (fr)
RU (1) RU2507205C2 (fr)
SG (1) SG171846A1 (fr)
SI (1) SI2370441T1 (fr)
TW (1) TWI379833B (fr)
UA (1) UA103504C2 (fr)
WO (1) WO2010060836A1 (fr)
ZA (1) ZA201103419B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013526537A (ja) * 2010-05-13 2013-06-24 アムジエン・インコーポレーテツド Ｐｄｅ１０阻害剤としてのヘテロアリールオキシカルボシクリル化合物
US8828989B2 (en) * 2011-09-26 2014-09-09 Hoffmann-La Roche Inc. Oxy-cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[E]azulenes as V1A antagonists
RU2014117471A (ru) * 2011-10-05 2015-11-10 Ф. Хоффманн-Ля Рош Аг ЦИКЛОГЕКСИЛ-4Н,6Н-5-ОКСА-2,3,10В-ТРИАЗАБЕНЗО[e]АЗУЛЕНЫ В КАЧЕСТВЕ АНТАГОНИСТОВ РЕЦЕПТОРА V1A
JP6427192B2 (ja) 2013-08-19 2018-11-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 位相変位睡眠障害を処置するためのＶ１ａアンタゴニスト
KR102384629B1 (ko) 2013-12-05 2022-04-11 에프. 호프만-라 로슈 아게 트랜스-8-클로로-5-메틸-1-[4-(피리딘-2-일옥시)-사이클로헥실]-5,6-다이하이드로-4H-2,3,5,10b-테트라아자-벤조[e]아줄렌 및 그의 결정 형태의 합성
WO2017191117A1 (fr) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft Antagonistes du récepteur v1a destinés à une utilisation dans le traitement de maladies rénales
RU2666598C1 (ru) * 2017-07-14 2018-09-11 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Средство для коррекции расстройств аутистического спектра
US11033601B2 (en) 2017-09-14 2021-06-15 The Regents Of The University Of Colorado, A Body Corporate Selective inhibition of V1b for treating fatty liver
EP3720424B1 (fr) 2017-12-08 2022-09-21 F. Hoffmann-La Roche AG Formulation pharmaceutique
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
WO2020139670A1 (fr) 2018-12-27 2020-07-02 Teva Pharmaceuticals International Gmbh Formes à l'état solide de balovaptan

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521173A (en) 1995-01-17 1996-05-28 American Home Products Corporation Tricyclic benzazepine vasopressin antagonists
BRPI9917086B8 (pt) 1999-01-19 2016-05-24 Ortho Mcneil Pharm Inc benzodiazepina tricíclica, suas composições farmacêuticas bem como compostos intermediários
TWI239333B (en) * 2000-11-16 2005-09-11 Hoffmann La Roche Benzodiazepine derivatives as GABA A receptor modulators
US7022699B2 (en) 2001-04-12 2006-04-04 Wyeth Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators
GB0303852D0 (en) 2003-02-19 2003-03-26 Pfizer Ltd Triazole compounds useful in therapy
GB0400700D0 (en) * 2004-01-13 2004-02-18 Pfizer Ltd Compounds useful in therapy
AP2006003768A0 (en) 2004-05-25 2006-10-31 Pfizer Prod Inc TetraazabenzoÄeÜazulene derivatives and analogs tehereof
KR100840852B1 (ko) 2004-05-25 2008-06-23 화이자 프로덕츠 인크. 테트라아자벤조[ｅ]아줄렌 유도체 및 이의 유사체
EP1632494A1 (fr) 2004-08-24 2006-03-08 Ferring B.V. Antagonistes de la v1a vasopressine
EP1784408A1 (fr) * 2004-08-25 2007-05-16 Pfizer Limited Triazolobenzodiazepines et leur utilisation en tant qu'antagonistes de la vasopressine
JP2008539220A (ja) 2005-04-26 2008-11-13 ファイザー・リミテッド バソプレシンアンタゴニストとしてのトリアゾール誘導体
EP1885713A1 (fr) 2005-05-18 2008-02-13 Pfizer Limited Derives de 1, 2, 4-triazole en tant qu'antagonistes de la vasopressine
KR101129791B1 (ko) 2007-01-12 2012-03-23 에프. 호프만-라 로슈 아게 스파이로피페리딘 글리신아마이드 유도체
US8617703B2 (en) * 2008-04-09 2013-12-31 Kuraray Co., Ltd. Gas barrier layered product and method for producing the same
CN102216305B (zh) 2008-11-13 2013-12-18 弗·哈夫曼-拉罗切有限公司 螺-5,6-二氢-4H-2,3,5,10b-四氮杂-苯并[e]薁类
AU2009317386B2 (en) * 2008-11-18 2013-07-25 F. Hoffmann-La Roche Ag Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
US8420633B2 (en) 2010-03-31 2013-04-16 Hoffmann-La Roche Inc. Aryl-cyclohexyl-tetraazabenzo[e]azulenes
US8461151B2 (en) 2010-04-13 2013-06-11 Hoffmann-La Roche Inc. Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes
US8492376B2 (en) 2010-04-21 2013-07-23 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes
US8481528B2 (en) 2010-04-26 2013-07-09 Hoffmann-La Roche Inc. Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes
US8513238B2 (en) 2010-05-10 2013-08-20 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes

Also Published As

Publication number Publication date
AR112338A2 (es) 2019-10-16
AU2009319123A1 (en) 2010-06-03
RU2507205C2 (ru) 2014-02-20
HK1160642A1 (en) 2012-08-10
IL212122A (en) 2013-06-27
WO2010060836A1 (fr) 2010-06-03
AR074409A1 (es) 2011-01-12
IL212122A0 (en) 2011-06-30
RU2011123703A (ru) 2013-01-10
PL2370441T3 (pl) 2014-02-28
TW201024300A (en) 2010-07-01
CR20110220A (es) 2011-06-21
NZ592076A (en) 2012-06-29
US8227458B2 (en) 2012-07-24
MY150837A (en) 2014-02-28
ECSP11011089A (es) 2011-06-30
US20120225865A1 (en) 2012-09-06
JP5452608B2 (ja) 2014-03-26
SG171846A1 (en) 2011-07-28
BRPI0922303A2 (pt) 2016-01-12
ES2431279T3 (es) 2013-11-25
CN102227428A (zh) 2011-10-26
CO6341478A2 (es) 2011-11-21
PE20110582A1 (es) 2011-08-17
EP2370441A1 (fr) 2011-10-05
EP2370441B1 (fr) 2013-09-11
BRPI0922303B1 (pt) 2019-11-12
CN102227428B (zh) 2015-03-25
KR20110077022A (ko) 2011-07-06
CY1115435T1 (el) 2017-01-04
ZA201103419B (en) 2014-07-30
US8461152B2 (en) 2013-06-11
TWI379833B (en) 2012-12-21
HRP20131067T1 (hr) 2013-12-06
MX2011005596A (es) 2011-06-16
DK2370441T3 (da) 2013-10-21
JP2012510441A (ja) 2012-05-10
AU2009319123B2 (en) 2014-10-23
CA2743976A1 (fr) 2010-06-03
SI2370441T1 (sl) 2013-12-31
PT2370441E (pt) 2013-11-14
KR101359742B1 (ko) 2014-02-06
UA103504C2 (ru) 2013-10-25
US20100137286A1 (en) 2010-06-03
CA2743976C (fr) 2017-02-21

Similar Documents

Publication Publication Date Title
MA32781B1 (fr) Arycyclohexylethers de dihydrotetrazabenzoazulenes pour emploi en tant qu'antagonistes du recepteur v1a de la vasopressine
MA34174B1 (fr) Hetéroaryl-cyclohexyl-tétraazabenzo[e)azulènes comme antagonistes des récepteurs de la vasopressine v1a
MA34252B1 (fr) Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes
MA34173B1 (fr) Hhétérobiaryl-cyclohexyl-tétraazabenzo[e]azulènes
MA29411B1 (fr) 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa
MA33920B1 (fr) Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide
MA30289B1 (fr) Dérivés d'amines
MY147588A (en) (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
MA31283B1 (fr) Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse
MA29568B1 (fr) Composes d'azaindazole et methodes d'utilisation desdits composes
WO2008080844A9 (fr) Dérivés azaspiro
MA30778B1 (fr) Derives de sulfonamides servant d'agonistes adrenergique et d'antagonistes muscariniques
TN2009000138A1 (fr) Biaryl-ether-urees
MA33239B1 (fr) 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires
MA31952B1 (fr) Pyrrolopyrimidines et pyrrolopyridines
MA29839B1 (fr) Derives de carboxamides servant d'antagonistes des recepteurs muscariniques
MA33274B1 (fr) Dérivés de la thiéno [2, 3-b] pyridine servant d'inhibiteurs de réplication virale
MA35271B1 (fr) Antagonistes de trpm8 et leur utilisation dans des traitements
MA30406B1 (fr) Nouveaux composes
EA200801184A1 (ru) Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2
MA32798B1 (fr) Acides naphtylacétiques
EP2202222A3 (fr) Dérivés d'indène, leur préparation et leur utilisation en tant que médicaments
MA30313B1 (fr) Amines secondaires en tant qu'inhibiteurs de la renine
MA35874B1 (fr) Dérivés d'amide cycliques à utiliser en tant qu'inhibiteurs de 11-bêta-hydroxystéroïde déshydrogénase et utilisations de ceux-ci
MA35444B1 (fr) Ligands du récepteur ep1